The U.S. Food and Drug Administration (FDA) has approved Moderna's first mRNA-based flu vaccine, marking a significant advancement in influenza prevention. This approval signifies the broader application of mRNA technology, previously known for its role in COVID-19 vaccines, to combat seasonal influenza. The vaccine, known as mFlusiva, is designed to protect against the most common strains of the flu virus.
5h ago
The NCAA is embroiled in a series of lawsuits across the United States challenging its eligibility rules, primarily stemming from the org…
## The Background
## The Background A Canadian citizen, Kaitlyn Tracey, is facing deportation from the United States following an alleged assault incident …
Morning Briefing
The five stories our editors are watching before markets open.
Letter from the Editor
How we report, correct errors, and how readers can reach us.
Newsletters
Weekly digests for politics, tech, and culture—free to subscribe.
August 6, 2026
August 6, 2026
SpaceX's stock experienced a significant drop of 7% in the wake of its latest earnings report, despite the company exceeding revenue expectations. This decline, observed on August 5, 2026, has prompted analysts to re-evaluate price targets. The primary driver behind investor concern appears to be the company's substantial increase in artificial intelligence (AI) spending, which has overshadowed the positive revenue figures and raised questions about future profitability and valuation.
1d ago
## The Background
1d ago
## The Background: Public Figures and Mental Health Crises
1d ago
